Quarterly report · Q2
2372.TEDINET S100S4U1
Period2023-04-01 → 2023-09-30
Filed2023-11-07
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 48
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥8.7bn | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Revenue | ¥18.4bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥9.6bn | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Operating income | ¥790m | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Operating income | ¥2.4bn | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Ordinary income | ¥1.2bn | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥3.3bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥2.5bn | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥1.4bn | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥2.6bn | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥1.1bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥2.5bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥2.0bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥1.1bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Net income | ¥2.0bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Total assets | ¥36.2bn | at 2023-09-30 | Cons. | Assets |
| Total assets | ¥35.1bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥30.4bn | at 2022-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥23.3bn | at 2023-09-30 | Cons. | Liabilities |
| Total liabilities | ¥23.0bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥13.0bn | at 2023-09-30 | Cons. | Net assets |
| Net assets / equity | ¥12.2bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥12.0bn | at 2022-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥8.9bn | at 2023-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥9.4bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥8.9bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥9.4bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥7.0bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥6.4bn | at 2022-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥803m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥3.6bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥2.5bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥1.3bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥4.8bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥2.7bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥17m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥4.3bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥740m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥90.22 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥16.56 | 2023-07-01 → 2023-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥210.22 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥164.17 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥75.8 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥210.06 | 2022-04-01 → 2023-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥163.91 | 2022-04-01 → 2022-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 35.7% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 34.6% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 39.2% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 62
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-04-01 → 2023-09-30 | ¥250m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-04-01 → 2023-09-30 | ¥219m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥31m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-04-01 → 2023-09-30 | −¥542m |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-09-30 | −¥2.4bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-09-30 | −¥2.4bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-09-30 | −¥764m |
| jpcrp040300-q2r_E05352-000Advanced Medicalreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥1.7bn |
| jpcrp040300-q2r_E05352-000Advanced Medicalreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥844m |
| jpcrp040300-q2r_E05352-000Advanced Medicalreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥885m |
| jpcrp040300-q2r_E05352-000Advanced Medicalreportable segment | segment profit | 2023-04-01 → 2023-09-30 | −¥23m |
| jpcrp040300-q2r_E05352-000CROreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥3.4bn |
| jpcrp040300-q2r_E05352-000CROreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥2.8bn |
| jpcrp040300-q2r_E05352-000CROreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥610m |
| jpcrp040300-q2r_E05352-000CROreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥66m |
| jpcrp040300-q2r_E05352-000Medical Supportreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥943m |
| jpcrp040300-q2r_E05352-000Medical Supportreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥533m |
| jpcrp040300-q2r_E05352-000Medical Supportreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥409m |
| jpcrp040300-q2r_E05352-000Medical Supportreportable segment | segment profit | 2023-04-01 → 2023-09-30 | −¥35m |
| jpcrp040300-q2r_E05352-000SMOreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥4.8bn |
| jpcrp040300-q2r_E05352-000SMOreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥4.3bn |
| jpcrp040300-q2r_E05352-000SMOreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥490m |
| jpcrp040300-q2r_E05352-000SMOreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥2.1bn |
| —segment total | revenue | 2023-04-01 → 2023-09-30 | ¥10.9bn |
| —segment total | revenue external | 2023-04-01 → 2023-09-30 | ¥8.5bn |
| —segment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥2.4bn |
| —segment total | segment profit | 2023-04-01 → 2023-09-30 | ¥2.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-09-30 | ¥11.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-09-30 | ¥8.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥2.4bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-09-30 | ¥1.6bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-04-01 → 2022-09-30 | ¥68m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-04-01 → 2022-09-30 | ¥28m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥39m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-04-01 → 2022-09-30 | −¥118m |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-09-30 | −¥641m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-09-30 | −¥641m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-09-30 | −¥673m |
| jpcrp040300-q2r_E05352-000Advanced Medicalreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥594m |
| jpcrp040300-q2r_E05352-000Advanced Medicalreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥592m |
| jpcrp040300-q2r_E05352-000Advanced Medicalreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥1m |
| jpcrp040300-q2r_E05352-000Advanced Medicalreportable segment | segment profit | 2022-04-01 → 2022-09-30 | −¥184m |
| jpcrp040300-q2r_E05352-000CROreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥2.8bn |
| jpcrp040300-q2r_E05352-000CROreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥2.7bn |
| jpcrp040300-q2r_E05352-000CROreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥88m |
| jpcrp040300-q2r_E05352-000CROreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥82m |
| jpcrp040300-q2r_E05352-000Medical Supportreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥978m |
| jpcrp040300-q2r_E05352-000Medical Supportreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥528m |
| jpcrp040300-q2r_E05352-000Medical Supportreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥449m |
| jpcrp040300-q2r_E05352-000Medical Supportreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥28m |
| jpcrp040300-q2r_E05352-000SMOreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥5.8bn |
| jpcrp040300-q2r_E05352-000SMOreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥5.7bn |
| jpcrp040300-q2r_E05352-000SMOreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥61m |
| jpcrp040300-q2r_E05352-000SMOreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥3.3bn |
| —segment total | revenue | 2022-04-01 → 2022-09-30 | ¥10.2bn |
| —segment total | revenue external | 2022-04-01 → 2022-09-30 | ¥9.6bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥601m |
| —segment total | segment profit | 2022-04-01 → 2022-09-30 | ¥3.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-09-30 | ¥10.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-09-30 | ¥9.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥641m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-09-30 | ¥3.1bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 540
| Item | Context | Value | Unit |
|---|---|---|---|
| Decrease increase in notes and accounts receivable trade ope cf | Prior1YTDDuration | -405000000 | JPY |
| Decrease increase in notes and accounts receivable trade ope cf | CurrentYTDDuration | 291000000 | JPY |
| Increase decrease in notes and accounts payable trade ope cf | Prior1YTDDuration | 120000000 | JPY |
| Increase decrease in notes and accounts payable trade ope cf | CurrentYTDDuration | -90000000 | JPY |
| Increase decrease in contract liabilities ope cf | Prior1YTDDuration | 53000000 | JPY |
| Increase decrease in contract liabilities ope cf | CurrentYTDDuration | 186000000 | JPY |
| Increase decrease in deposits received ope cf | Prior1YTDDuration | 501000000 | JPY |
| Increase decrease in deposits received ope cf | CurrentYTDDuration | -163000000 | JPY |
| Increase decrease in accounts payable other ope cf | Prior1YTDDuration | 19000000 | JPY |
| Increase decrease in accounts payable other ope cf | CurrentYTDDuration | -243000000 | JPY |
| Other net ope cf | Prior1YTDDuration | -12000000 | JPY |
| Other net ope cf | CurrentYTDDuration | -245000000 | JPY |
| Subtotal ope cf | Prior1YTDDuration | 2880000000 | JPY |
| Subtotal ope cf | CurrentYTDDuration | 1095000000 | JPY |
| Interest and dividends income received ope cf inv cf | Prior1YTDDuration | 4000000 | JPY |
| Interest and dividends income received ope cf inv cf | CurrentYTDDuration | 8000000 | JPY |
| Interest expenses paid ope cf fin cf | Prior1YTDDuration | -62000000 | JPY |
| Interest expenses paid ope cf fin cf | CurrentYTDDuration | -83000000 | JPY |
| Income taxes paid refund ope cf | Prior1YTDDuration | -344000000 | JPY |
| Income taxes paid refund ope cf | CurrentYTDDuration | -260000000 | JPY |
| Proceeds from subsidy income2 ope cf | Prior1YTDDuration | 55000000 | JPY |
| Proceeds from subsidy income2 ope cf | CurrentYTDDuration | 43000000 | JPY |
| Net cash provided by used in operating activities | Prior1YTDDuration | 2533000000 | JPY |
| Net cash provided by used in operating activities | CurrentYTDDuration | 803000000 | JPY |
| Purchase of investment securities inv cf | Prior1YTDDuration | -925000000 | JPY |
| Purchase of investment securities inv cf | CurrentYTDDuration | -232000000 | JPY |
| Purchase of property plant and equipment inv cf | Prior1YTDDuration | -1795000000 | JPY |
| Purchase of property plant and equipment inv cf | CurrentYTDDuration | -1982000000 | JPY |
| Proceeds from sales of property plant and equipment inv cf | Prior1YTDDuration | 315000000 | JPY |
| Proceeds from sales of property plant and equipment inv cf | CurrentYTDDuration | 1109000000 | JPY |
| Purchase of memberships inv cf | Prior1YTDDuration | -153000000 | JPY |
| Purchase of memberships inv cf | CurrentYTDDuration | -12000000 | JPY |
| Payments of loans receivable inv cf | Prior1YTDDuration | -6000000 | JPY |
| Payments of loans receivable inv cf | CurrentYTDDuration | -105000000 | JPY |
| Collection of loans receivable inv cf | Prior1YTDDuration | 71000000 | JPY |
| Collection of loans receivable inv cf | CurrentYTDDuration | 31000000 | JPY |
| Payments for lease and guarantee deposits inv cf | Prior1YTDDuration | -235000000 | JPY |
| Payments for lease and guarantee deposits inv cf | CurrentYTDDuration | -8000000 | JPY |
| Other net inv cf | Prior1YTDDuration | 6000000 | JPY |
| Other net inv cf | CurrentYTDDuration | -118000000 | JPY |
| Net cash provided by used in investment activities | Prior1YTDDuration | -2723000000 | JPY |
| Net cash provided by used in investment activities | CurrentYTDDuration | -1318000000 | JPY |
| Net increase decrease in short term loans payable fin cf | Prior1YTDDuration | － | JPY |
| Net increase decrease in short term loans payable fin cf | CurrentYTDDuration | 500000000 | JPY |
| Proceeds from long term loans payable fin cf | Prior1YTDDuration | 1836000000 | JPY |
| Proceeds from long term loans payable fin cf | CurrentYTDDuration | 711000000 | JPY |
| Repayment of long term loans payable fin cf | Prior1YTDDuration | -731000000 | JPY |
| Repayment of long term loans payable fin cf | CurrentYTDDuration | -737000000 | JPY |
| Cash dividends paid fin cf | Prior1YTDDuration | -301000000 | JPY |
| Cash dividends paid fin cf | CurrentYTDDuration | -362000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |